Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Study acronym: SURF303
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 230 → 285 participants
    • Interventions modified
    • Trial arms changed: 3 → 2
    • Eligibility criteria shortened, about 8 words
  2. Re-verified, no change to tracked fields
  3. Trial sites expanded: 26 → 32 locations
  4. Eligibility criteria expanded, about 31 words
    • Site details revised at 1 of 26 sites
  5. Trial sites expanded: 21 → 24 locationsv23
  6. Study sites: 24 to 25v22
  7. Trial sites expanded: 18 → 21 locationsv21
  8. Study sites: 18 to 21v20
  9. Study sites: 17 to 18v19
  10. Study sites: 16 to 17v18
  11. Re-verified, no change to tracked fieldsv17
  12. Study sites: 15 to 16v16
  13. Study sites: 14 to 15v15
  14. Study sites: 13 to 14v14
  15. Study sites: 12 to 13v13
  16. Study sites: 11 to 12v12
  17. Study sites: 10 to 11v11
  18. Study sites: 9 to 10v10
  19. Study sites: 7 to 9v9
  20. Study sites: 6 to 7v8
  21. Study sites: 5 to 6v7
  22. Study sites: 4 to 5v6
  23. Study sites: 3 to 4v5
  24. Study sites: 2 to 3v4
  25. Study sites: 1 to 2v3
  26. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2025 to Dec 22, 2025
    v2
  27. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Trial Details
NCT Number NCT07265947
Lead Sponsor Tyra Biosciences, Inc
Conditions
(from sponsor)		 Low Grade Upper Tract Urothelial Carcinoma
Enrollment 285 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov